StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Amgen (AMGN) PT Raised to $195 at Argus on 2Q Report; 'Contributors to Top-Line Growth: Kyprolis, Prolia & Sensipar'
July 27, 2017 10:11 AM
Argus raised its price target on Amgen (NASDAQ: AMGN) to $195.00 (from ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS Change
Analyst EPS View
Analyst PT Change
Next Articles
Amgen (AMGN) Reports Submission of Supplemental Biologics License Application For Prolia (denosumab)
July 31, 2017 9:12 AM
Amgen (AMGN) & Allergan (AGN) Report U.S. FDA Submission of Biosimilar Biologics License Application For ABP 980
July 31, 2017 9:03 AM
Amgen (AMGN) Declares $1.15 Quarterly Dividend; 2.6% Yield
July 28, 2017 4:01 PM
Amgen (AMGN) PT Raised to $180 at UBS Following Solid 2Q
July 26, 2017 8:34 AM
Amgen (AMGN): Strong Q2 2017; Raising Target Price - Oppenheimer
July 26, 2017 6:23 AM
Amgen (AMGN) PT Raised to $174 at Deutsche Bank
July 26, 2017 6:18 AM
BMO Capital Downgrades Amgen (AMGN) to Market Perform
July 26, 2017 5:09 AM
Amgen (AMGN) Tops Q2 EPS by 16c, Lifts FY Guidance
July 25, 2017 4:04 PM
